24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
DASALIEVA 50MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | DASALIEVA 50MG |
|---|---|
| Composition | Dasatinib Tablet IP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (60Tab) |
| Country of Origin | India |
DASALIEVA 50MG (Dasatinib Tablet IP 50mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
DASALIEVA 50 MG (Dasatinib Tablet IP 50 mg) is a prescription anticancer medicine containing Dasatinib 50 mg, a targeted therapy used for the treatment of specific types of blood cancers, particularly Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Dasatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs), which work by blocking abnormal proteins that promote the growth and survival of cancer cells.
Blood cancers such as CML occur when genetic mutations cause abnormal white blood cells to multiply uncontrollably. One of the key abnormalities associated with these cancers is the formation of the BCR-ABL protein, which continuously signals cancer cells to grow and divide. DASALIEVA 50 MG targets and inhibits this protein, helping to slow disease progression and control cancer growth.
Unlike traditional chemotherapy, Dasatinib is a targeted therapy designed to specifically attack cancer-related pathways while minimizing damage to healthy cells. This targeted mechanism has made Dasatinib an important treatment option for patients diagnosed with certain forms of leukemia.
DASALIEVA 50 MG is commonly prescribed for:
The medicine is widely used in hematology and oncology practices and may be prescribed as first-line treatment or for patients who have not responded adequately to other therapies.
Manufactured according to stringent pharmaceutical quality standards, DASALIEVA 50 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Dasatinib therapy require regular medical monitoring, including complete blood counts, liver function tests, and clinical evaluations to assess treatment response and detect potential side effects.
Due to its proven effectiveness in leukemia management, DASALIEVA 50 MG remains an essential targeted therapy in modern cancer care worldwide.
DASALIEVA 50 MG (Dasatinib Tablet IP 50 mg) is primarily used for the treatment and long-term management of specific blood cancers.
The medicine is widely used for treating patients diagnosed with chronic myeloid leukemia.
Dasatinib may be prescribed as a first-line treatment for newly diagnosed chronic phase CML.
The medicine may be used when patients do not respond adequately to previous therapies.
Doctors may prescribe Dasatinib for patients unable to tolerate other treatment options.
The medicine is used in selected patients with this aggressive form of leukemia.
Dasatinib may be included in treatment programs for advanced disease stages.
The medicine helps control disease progression and maintain treatment response.
Dasatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
DASALIEVA works by:
This targeted action helps manage leukemia while preserving healthy tissues.
Like all medicines, DASALIEVA 50 MG may cause side effects in some patients. Side effects vary depending on treatment duration and individual response.
Patients may experience weakness and tiredness during treatment.
Mild to moderate headaches may occur.
Some individuals may experience nausea.
Loose stools and digestive discomfort may develop.
Mild skin reactions can occur during therapy.
Muscle aches and discomfort may be reported.
Swelling of the hands, feet, or face may occur.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of DASALIEVA 50 MG (Dasatinib Tablet IP 50 mg) should always be determined by a qualified hematologist or oncologist.
The dosage may vary depending on the type and stage of leukemia.
Treatment plans may differ based on patient-specific requirements.
Previous therapies and overall health status influence dosage decisions.
Laboratory findings help guide treatment planning and dose adjustments.
Doctors may modify dosage according to effectiveness and tolerability.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).
Dasatinib is a targeted anticancer medicine known as a Tyrosine Kinase Inhibitor (TKI) that blocks abnormal proteins involved in cancer cell growth.
No. It is a targeted therapy that works differently from traditional chemotherapy medicines.
Yes, it is commonly prescribed as a first-line treatment for certain patients with Chronic Myeloid Leukemia.
Yes, the medicine may lower blood cell counts, requiring regular monitoring during treatment.
Treatment duration varies depending on the patient's condition, treatment response, and physician recommendations.
Yes, routine blood tests and medical evaluations are important to ensure treatment safety and effectiveness.
Yes, this medicine should only be used under the guidance of qualified healthcare professionals experienced in hematology and oncology treatment.